Clinical Trial Update: Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluated avelumab with chemoradiation for resectable stage II/III esophageal and gastroesophageal cancer; the study has completed and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Cancer

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Resectable Esophageal Cancer, GastroEsophageal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-07-26